High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

INTRODUCTION: This multicenter review evaluated the efficacy and safety of osimertinib dose escalation for central nervous system (CNS) progression developing on osimertinib 80 mg in EGFR-mutant NSCLC. METHODS: Retrospective review identified 105 patients from eight institutions with advanced EGFR-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Piper-Vallillo, A.J., Rotow, Julia K., Aredo, Jacqueline V., Shaverdashvili, Khvaramze, Luo, Jia, Carlisle, Jennifer W., Husain, Hatim, Muzikansky, Alona, Heist, Rebecca S., Rangachari, Deepa, Ramalingam, Suresh S., Wakelee, Heather A., Yu, Helena A., Sequist, Lecia V., Bauml, Joshua M., Neal, Joel W., Piotrowska, Zofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142556/
https://www.ncbi.nlm.nih.gov/pubmed/35637759
http://dx.doi.org/10.1016/j.jtocrr.2022.100328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142556/
https://www.ncbi.nlm.nih.gov/pubmed/35637759
http://dx.doi.org/10.1016/j.jtocrr.2022.100328

Ejemplares similares